Pseurotin A Validation as a Metastatic Castration-Resistant Prostate Cancer Recurrence-Suppressing Lead via PCSK9-LDLR Axis Modulation
Marine Drugs · 2023
DOI: 10.3390/md21040215 ↗Kurz gefasst
Fachartikel in der Zeitschrift Marine Drugs, 2023. Verfasst von Khaldoun S Abdelwahed und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy, University of Louisiana at Monroe, Monroe, LA 71201, USA. Hauptthemen laut MEDLINE: Proprotein Convertase 9, Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute, VCOM FY22 Delta Collaborative Research Program (Delta-CRP).
Abstract (Originalsprache)
Metastatic castration-resistant prostate cancer (mCRPC) cells can de novo biosynthesize their own cholesterol and overexpress proprotein convertase subtilisin/kexin type 9 (PCSK9). PCSK9 proved to contribute to mCRPC cell motility since PCSK9 knockdown (KD) in mCRPC CWR-R1ca cells led to notable reductions in cell migration and colony formation. Human tissue microarray results proved a higher immunohistoscore in patients ≥ 65 years old, and PCSK9 proved to be expressed higher at an early Gleason score of ≤7. The fermentation product pseurotin A (PS) suppressed PCSK9 expression, protein–protein interactions with LDLR, and breast and prostate cancer recurrences. PS suppressed migration and colony formation of the CWR-R1ca cells. The progression and metastasis of the CWR-R1ca-Luc cells subcutaneously (sc) xenografted into male nude mice fed a high-fat diet (HFD, 11% fat content) showed nearly 2-fold tumor volume, metastasis, serum cholesterol, low-density lipoprotein cholesterol (LDL-C), prostate-specific antigen (PSA), and PCSK9 levels versus mice fed a regular chow diet. Daily oral PS 10 mg/kg treatments prevented the locoregional and distant tumor recurrence of CWR-R1ca-Luc engrafted into nude mice after primary tumor surgical excision. PS-treated mice showed a significant reduction in serum cholesterol, LDL-C, PCSK9, and PSA levels. These results comprehensively validate PS as an mCRPC recurrence-suppressive lead by modulating the PCSK9-LDLR axis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy, University of Louisiana at Monroe, Monroe, LA 71201, USA.
- Department of Surgery, School of Medicine, Tulane University, New Orleans, LA 70112, USA.
- Department of Biomedical Sciences, Discipline of Pharmacology, Edward Via College of Osteopathic Medicine, University of Louisiana at Monroe, Monroe, LA 71203, USA.
ORCID-Profile: Hassan Y Ebrahim, Ethar A Mudhish, Ashkan H Rad, Zakaria Y Abd Elmageed, Khalid A El Sayed
Förderung
- NCI NIH HHS
- National Cancer Institute
- VCOM FY22 Delta Collaborative Research Program (Delta-CRP)
Zitieren
APA
Abdelwahed, K. S., Siddique, A. B., Ebrahim, H. Y., Qusa, M. H., Mudhish, E. A., Rad, A. H., Zerfaoui, M., Abd Elmageed, Z. Y., & El Sayed, K. A. (2023). Pseurotin A Validation as a Metastatic Castration-Resistant Prostate Cancer Recurrence-Suppressing Lead via PCSK9-LDLR Axis Modulation. Marine Drugs. https://doi.org/10.3390/md21040215
Vancouver
Abdelwahed KS, Siddique AB, Ebrahim HY, Qusa MH, Mudhish EA, Rad AH, et al. Pseurotin A Validation as a Metastatic Castration-Resistant Prostate Cancer Recurrence-Suppressing Lead via PCSK9-LDLR Axis Modulation. Marine Drugs. 2023. doi:10.3390/md21040215
BibTeX
@article{Abdelwahed2023,
author = {Abdelwahed, Khaldoun S and Siddique, Abu Bakar and Ebrahim, Hassan Y and Qusa, Mohammed H and Mudhish, Ethar A and Rad, Ashkan H and Zerfaoui, Mourad and Abd Elmageed, Zakaria Y and El Sayed, Khalid A},
title = {Pseurotin A Validation as a Metastatic Castration-Resistant Prostate Cancer Recurrence-Suppressing Lead via PCSK9-LDLR Axis Modulation},
journal = {Marine Drugs},
year = {2023},
doi = {10.3390/md21040215}
}
EUVIMED